Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
392 Leser
Artikel bewerten:
(2)

Mile High Labs and Royal DSM Announce Exclusive Strategic Partnership to Develop and Commercialize the Next Generation of Science-Backed Cannabinoid Consumer Products

BROOMFIELD, Colo., June 15, 2021 /PRNewswire/ -- Mile High Labs (MHL) and Royal DSM (DSM) are pleased to announce that they have entered into a broad commercial partnership, combining MHL's industry-leading cannabinoid ingredients and finished products manufacturing expertise with DSM's science-based nutritional solutions. The partnership creates a platform from which leading consumer products companies can innovate and deliver novel consumer goods with globally trusted, health-benefit driven ingredients. The relationship will also see MHL and DSM partner in the development of unique hemp-derived cannabinoid product solutions.

"In a time like no other, I am deeply proud to ink this exclusive strategic relationship," said Jonathan Hilley, Chief Executive Officer, Mile High Labs. "DSM is a trusted, end-to-end partner to many of the largest consumer packaged goods companies globally. Their unmatched portfolio and mission-driven approach makes DSM one of the most important consumer companies in the world. Together, we are creating the first of its kind-a novel product development platform that supports customers in achieving rapid, scalable growth and puts the enormous legal cannabinoid opportunity within reach."

Enabled by MHL's large-scale 400,000 square feet of manufacturing facilities, the partnership will provide DSM's customers with access to MHL's portfolio of specialty cannabinoid ingredients like CBD, CBG and CBN, as well as its rapid R&D and prototyping capabilities, formulation know-how, and manufacturing, packaging and distribution infrastructure. The partnership will also see DSM apply its advanced scientific, applications and formulations expertise to products combining high-quality micronutrients with CBD and other hemp derivatives. The resulting market-ready and premix solutions will allow dietary supplement, food, beverage, wellness and nutrition brands to deliver science-backed, health-benefit driven innovation with speed and confidence.

MHL's customers will gain access to DSM's broad portfolio of science-backed products-and novel products built upon the DSM foundation-with structure-function data to support health-benefit product claims. For the first time, leading CBD brands will be able to leverage decades of scientific evidence to communicate specifically what their product does. Together, DSM and MHL are delivering a turnkey solution that empowers customers to confidently develop, launch and scale new products in this booming segment of the health and wellness industry.

"There is a strong consumer pull in the CBD space for high-quality, health-benefit driven solutions, but the market has yet to establish the quality standards necessary to support global brands. DSM has the core competencies, combined with a deep understanding of consumer and customer needs, to help brands enter the cannabinoid market early and build a leading position," Frederic Boned, Vice President, Human Nutrition & Health at DSM North America commented. "MHL is the ideal partner due to its staunch commitment to sustainability, quality and regulatory compliance, as well as its extensive cannabinoid manufacturing capabilities. Together, we are committed to developing the science and quality standards the cannabinoid industry sorely needs. Our complementary areas of expertise will support customers along the entire product development process."

"DSM is uniquely capable of recognizing the Mile High vision and amplifying it," adds Hilley. "Together, we look forward to delivering cannabinoid innovation that is scalable, sustainable, cost-effective and provides the building blocks for exciting new consumer products. We are building a better path to wellness-both for companies seeking to innovate with legal cannabinoids and for the consumers who count on them."

To find out how MHL and DSM can help you get to market faster with purpose-led, market-ready solutions, contact sales@milehighlabs.com.

About Mile High Labs

Mile High Labs powers the world's novel consumer packaged goods. Our portfolio of legal cannabinoid ingredients and market-ready solutions is trusted by leading global brands, and our formulation and rapid prototyping capabilities are creating the next generation of innovative consumer products. We specialize in the production of hemp cannabinoid-based powders, capsules, tablets and gummies, along with other value-added capabilities. With 400,000 square feet of research and manufacturing facilities in Broomfield, Colorado, as well as third-party fulfillment services to more than 35 countries, we empower customers to confidently develop, launch and scale new products backed by science and integrity. Learn more at www.MileHighLabs.com.

About DSM:

At DSM, we take pride in understanding the true potential of our customers' products and how they can help our planet's growing population stay healthy and ready to meet whatever challenge life provides. With our unique purpose-led perspective, DSM helps customers contribute to a brighter world with better nutrition for all. Because where other providers merely see products, we see purpose. As a reliable, end-to-end, innovative, purpose-led partner, DSM provides more than ingredients. We provide the most integrated offering in the industry. We offer a broad portfolio of science-backed products and customized solutions powered by expert services aimed at supporting a product's entire life cycle, from concept to consumer. This takes more than ingredients; it takes a partner. Find out more at www.PartnerWithDSM.com.

Contact:

John Husak
j.husak@milehighlabs.com

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.